

ABBREVED CURRICULUM VITAE (CVA) – maximum 4 PAGES

Instructions to fill this document are available in the website

Part A. PERSONAL INFORMATION

CV date

2022/12/13

First and Family name	José Antonio Encinar		
Social Security, Passport, ID number	06564821T	Age	54
Researcher codes	Open Researcher and Contributor ID (ORCID**)	http://orcid.org/0000-0002-7219-3863	
	SCOPUS Author ID (*)	35268584800	
	WoS Researcher ID (*)	42659790	

(*) *Optional*

(**) *Mandatory*

A.1. Current position

Name of University/Institution	Universidad Miguel Hernández de Elche		
Department	Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE)		
Address and Country	Av. de la Universidad. Desp. 2.08 Edif. Torregaitan. E-03202. Spain		
Phone number	+34 966658453	E-mail	Jant.encinar@umh.es
Current position	Profesor Titular de Universidad	From	2009
Key words	structural biocomputing, protein structure, molecular docking and dynamics, cancer		

A.2. Education

PhD, Licensed, Graduate	University	Year
Licenciado en CC Biológicas	Universidad de Salamanca	1992
Doctor	Universidad Miguel Hernández de Elche	1998

A.3. Career breaks*

Date	Reason	Duration (months)

* if applicable

A.4. General indicators of quality of scientific production (see instructions)

Date of the last four six-year period of investigation granted: June 12, 2018 for 2012-2017.

Number of doctoral theses supervised in the last 10 years: 1.

Total citations: 2355 (December 2022). h-index: 29 (source Google scholar)

<https://scholar.google.com/citations?user=jTdMuycAAAAJ>

Part B. CV SUMMARY (max. 3500 characters, including spaces)

José Antonio Encinar is associate professor (Profesor Titular de Universidad) of Biochemistry and Molecular Biology at the Department of Biochemistry and Molecular Biology, Miguel Hernández de Elche University. He obtained his doctorate (Biochemistry-Neuroscience) in 1998 (Instituto de Neurociencias de Alicante). He has been awarded the extraordinary doctoral prize in the Neurosciences program. He has completed two postdoctoral stays in Paris (Institut de Biologie Physico-Chimique. Prof. Philippe Devaux) and Heidelberg (European Molecular Biology Laboratory. Prof. Luis Serrano). His current research interests are focused on the use of computational approaches for the development of compounds that modulate the activity of proteins of biomedical interest (cancer, obesity, diabetes). The use of molecular modeling, docking and dynamics techniques allows high-throughput screening of chemical libraries for the selection of candidate compounds to modulate the activity of proteins of interest, which are then tested on the bench. To date, he has co-published 87 primary and review articles. He is currently developing his research activity at the Institute for Research, Development and Innovation in Health Biotechnology of Elche (IDiBE). As a professor, Dr. Encinar has



participated in multiple teaching activities for the Bachelor degrees of Biochemistry, Biotechnology and Food Science and Technology (EPSO-UMH).

Part C. RELEVANT MERITS (sorted by typology)

C.1. Publications (Publications during the last 10 years.)

All my publications are available on the web at <https://shaker.umh.es/publications/>

- [48] Verdura et al. *Cancers*. 2022; 14(24), 6101. DOI: [10.3390/cancers14246101](https://doi.org/10.3390/cancers14246101)
- [47] Srivastava et al. *F. Rad. Biol. and Med.* 2022; 192, 246-260. DOI: [10.1016/j.freeradbiomed.2022.09.023](https://doi.org/10.1016/j.freeradbiomed.2022.09.023)
- [46] Verdura et al. *Int. J. of Mol. Sciences*, 2022; 23(17), 9986. DOI: [10.3390/ijms23179986](https://doi.org/10.3390/ijms23179986)
- [45] Fernández-Ginés et al. *Red. Biol.* 2022; 55, 102396. DOI: [10.1016/j.redox.2022.102396](https://doi.org/10.1016/j.redox.2022.102396)
- [44] Falco et al. *Mar. Drugs* 2022; 20(6), 363. DOI: [10.3390/md20060363](https://doi.org/10.3390/md20060363)
- [43] Babiloni-Chust et al. *Environ Int.* 2022; 164, 107250. DOI: [10.1016/j.envint.2022.107250](https://doi.org/10.1016/j.envint.2022.107250)
- [42] Alberola-Die et al. *Int. J. Mol. Sci.* 2021; 22, 11287. DOI: [10.3390/ijms222011287](https://doi.org/10.3390/ijms222011287)
- [41] Ortega-Muelas et al. *J Cell Mol Med.* 2021;00, 1-13. DOI: [10.1111/jcmm.16990](https://doi.org/10.1111/jcmm.16990)
- [40] Tramonti et al. *Cancers* 2021, 13(16), 4009. DOI: [10.3390/cancers13164009](https://doi.org/10.3390/cancers13164009)
- [39] Marroqui et al. *Chemosphere.* 2021; 265: 129051. DOI: [10.1016/j.chemosphere.2020.129051](https://doi.org/10.1016/j.chemosphere.2020.129051)
- [38] Fuentes-Baile et al. *Cancers* 2020, 12(12), 3717. DOI: [10.3390/cancers12123717](https://doi.org/10.3390/cancers12123717)
- [37] Herranz-López et al. *Food Chem Toxicol.* 2020; 144:111606. DOI: [10.1016/j.fct.2020.111606](https://doi.org/10.1016/j.fct.2020.111606)
- [36] Rubio-Camacho et al. *Biomolecules* 2020, 10(7), 1015. DOI: [10.3390/biom10071015](https://doi.org/10.3390/biom10071015)
- [35] Bosch-Barrera et al. *J. Clin. Med.* 2020, 9(6), 1770. DOI: [10.3390/jcm9061770](https://doi.org/10.3390/jcm9061770)
- [34] Encinar and Menendez. *Viruses* 2020, 12(5), 525. DOI: [10.3390/v12050525](https://doi.org/10.3390/v12050525)
- [33] Cuyàs et al. *Aging* 2020, 12(6): 4794-4814. DOI: [10.18632/aging.102887](https://doi.org/10.18632/aging.102887)
- [32] Galiano et al. *The Journal of Memb. Biol.* 2020, 1-14. DOI: [10.1007/s00232-020-00106-5](https://doi.org/10.1007/s00232-020-00106-5)
- [31] Verdura et al. *Aging* 2020, 12(1): 8-34. DOI: [10.18632/aging.102646](https://doi.org/10.18632/aging.102646)
- [30] Olivares-Vicente et al. 2019. *Nutrients*; 11(12), 2961. DOI: [10.3390/nu11122961](https://doi.org/10.3390/nu11122961)
- [29] Cuyàs et al. 2019. *Nutrients*; 11(7): 1656. DOI: [10.3390/nu11071656](https://doi.org/10.3390/nu11071656)
- [28] Cuyàs et al. 2019. *Food Chem Toxicol.* 132: 110645. DOI: [10.1016/j.fct.2019.110645](https://doi.org/10.1016/j.fct.2019.110645)
- [27] Cuyàs et al. 2019. *Food Chem Toxicol.* 128: 35-45. DOI: [10.1016/j.fct.2019.03.049](https://doi.org/10.1016/j.fct.2019.03.049)
- [26] Chico et al. 2019. *Front Immunol.* 2019; 10: 613. DOI: [10.3389/fimmu.2019.00613](https://doi.org/10.3389/fimmu.2019.00613)
- [25] Falco et al. 2019. *Mar Drugs.* 17(2). DOI: [10.3390/md17020087](https://doi.org/10.3390/md17020087)



- [24] Ruiz-Torres et al. 2018. *Marine Drugs*, 16(10), 385. DOI: [10.3390/md16100385](https://doi.org/10.3390/md16100385)
- [23] Álvarez-Martínez et al. 2018. *Current Med. Chem.* DOI: [10.2174/0929867325666181008115650](https://doi.org/10.2174/0929867325666181008115650)
- [22] Medina-Gali et al. 2018. *Fish Shellfish Immunol.* 82: 514-521. DOI: [10.1016/j.fsi.2018.08.056](https://doi.org/10.1016/j.fsi.2018.08.056)
- [21] Lama et al. 2018. *Fish Shellfish Immunol.* 82: 190-199. DOI: [10.1016/j.fsi.2018.08.004](https://doi.org/10.1016/j.fsi.2018.08.004)
- [20] Bello-Perez et al. 2018. *Drug Design, Development and Therapy*, 12: 2337-2359. DOI: [10.2147/DDDT.S171087](https://doi.org/10.2147/DDDT.S171087)
- [19] Olivares-Vicente et al. 2018. *Current Drug Metabolism*, 19: 351-369. DOI: [10.2174/1389200219666180220095236](https://doi.org/10.2174/1389200219666180220095236)
- [18] Micol et al. 2017. *Agro FOOD Industry Hi Tech.* vol. 28(5). SCOPUS: 2-s2.0-85033694815
- [17] Bello-Perez et al. 2017. *Molecular Immunology* 91: 145-155. DOI: [10.1016/j.molimm.2017.09.005](https://doi.org/10.1016/j.molimm.2017.09.005)
- [16] Herranz-López et al. 2017. *Nutrients*, 9(8), 907. DOI: [10.3390/nu9080907](https://doi.org/10.3390/nu9080907)
- [15] Micol and Encinar. 2017. *Agro FOOD Industry Hi Tech.* vol. 28(2). SCOPUS: 2-s2.0-85031772569
- [14] Ruiz-Torres et al. 2017. *Molecules*, 22(7): 1037. DOI: [10.3390/molecules22071037](https://doi.org/10.3390/molecules22071037)
- [13] Jiménez-Sánchez et al. 2017. *PLoS ONE*, 12(3): e0173074. DOI: [10.1371/journal.pone.0173074](https://doi.org/10.1371/journal.pone.0173074)
- [12] Bello et al. 2016. *J. Dev Comp Immunol.* 69: 33-40. DOI: [10.1016/j.dci.2016.12.001](https://doi.org/10.1016/j.dci.2016.12.001)
- [11] Galiano-Ibarra et al. 2016. *Drug Design, Development and Therapy*, 10: 3163-3181. DOI: [10.2147/DDDT.S117369](https://doi.org/10.2147/DDDT.S117369)
- [10] Encinar et al. 2015. *Drug Design, Development and Therapy.* 9: 5877-5895. DOI: [10.2147/DDDT.S93449](https://doi.org/10.2147/DDDT.S93449)
- [9] Molina et al. 2015. *J Biol Chem.* 290(42): 25745-25755. DOI: [10.1074/jbc.M115.669598](https://doi.org/10.1074/jbc.M115.669598)
- [8] Corral-Rodríguez et al. 2014. *Biochem J.* 464: 23-34. DOI: [10.1042/BJ20140409](https://doi.org/10.1042/BJ20140409)
- [7] López-Jiménez et al. 2014. *Antiviral Res.* 108: 14-24. DOI: [10.1016/j.antiviral.2014.04.009](https://doi.org/10.1016/j.antiviral.2014.04.009)
- [6] Poveda et al. 2014. *Biochim Biophys Acta.* 1838(6): 1560-1567. DOI: [10.1016/j.bbamem.2013.10.023](https://doi.org/10.1016/j.bbamem.2013.10.023)
- [5] Martínez-López et al. 2013. *Marine Drugs*, 11(7): 2328-2346. DOI: [10.3390/md11072328](https://doi.org/10.3390/md11072328)
- [4] Ibarra, M. et al. 2013. *Biochimica et Biophysica Acta*, 1828 (2013): 2553-2563. DOI: [10.1016/j.bbamem.2013.06.014](https://doi.org/10.1016/j.bbamem.2013.06.014)
- [3] Giudici et al. 2013. *BBA - Biomembranes*, 1828(2): 193-200. DOI: [10.1016/j.bbamem.2012.09.020](https://doi.org/10.1016/j.bbamem.2012.09.020)
- [2] Renart et al. 2012. *Biochemistry*, 51: 3891-3900. DOI: [10.1021/bi201497n](https://doi.org/10.1021/bi201497n)



[1] Navarro et al. 2012. *Biochemistry*, 51: 3470-3484. DOI: [10.1021/bi201574t](https://doi.org/10.1021/bi201574t)

C.2. Research projects (Last 5 years)

1. Development of a new nutraceutical product for obesity management using a multi-omic approach. Dr. Enrique Barraón. Ref.: PID2021-125188OB-C32. Ministerio de Ciencia e Innovación. Plan Estatal de Investigación Científica, Técnica y de Innovación. 2022-2025. 198.440 €
2. Desarrollo de nuevos fármacos inhibidores de CDK4 dirigidos contra la interfase CDK4-ciclinaD1 para el tratamiento del glioblastoma multiforme. Ref.: ILISABIO/2021/A01. Universidad Miguel Hernández de Elche. Dr. José Antonio Encinar. 2022. 5.000 €
3. Nuevos enfoques terapéuticos frente a enfermedades metabólicas: modulación de la ingesta de alimentos y del balance energético mediante nutracéuticos y neurotecnología. Ref.: PROMETEO/2021/059. Generalitat Valenciana. Dr. Vicente Micol. 2021-2024. 548.816 €.
4. Una innovadora aproximación metabonómica inductiva para la identificación de metabolitos derivados de polifenoles de la dieta y sus dianas moleculares. Ministerio de Ciencia, Innovación y Universidades. Dr. Vicente Micol. Ref: RTI2018-096724-B-C21. 2019-2021. 145.200 €
5. Plataforma en nAnoTEcnología Traslacional (PATENT). Ayudas para adquisición de infraestructuras y equipamiento de I+D+i por las universidades públicas valencianas y consorcios públicos de investigación adscritos a la Generalitat Valenciana. Dr. Antonio V. Ferrer Montiel. 2018-2019. 770.000 €
6. El carácter multifactorial de los polifenoles: una oportunidad para el desarrollo de herramientas terapéuticas frente a la obesidad y las enfermedades infecciosas. Ref.: PROMETEO/2016/006. Generalitat Valenciana. Dr. Vicente Micol. 2016-2019. 219.478 €.

C.3. Contracts, technological or transfer merits

Collaboration agreement for the constitution of the Mixed Research Group "Research into new technologies in the treatment and diagnosis of cancer". Foundation for the promotion of sanitary and biomedical research of the Valencian community (FISABIO). Antonio Vicente Ferrer Montiel. 28/07/2015-28/07/2019.

C.4. Patents

TREATMENT OF NRF2-RELATED DISEASES. Patente solicitada 15-01-2021. Inventores: Antonio Cuadrado Pastor (45%), Raquel Fernández Ginés (15%), **José Antonio Encinar** (15%), Rafael León Martínez (5%), Juan Felipe Franco González (5%), Manuel García López (5%), María Isabel Rodríguez Franco (5%), Ana Isabel Rojo Sanchís (5%). PHAR compound has been submitted for international patent (application number PCT/EP2022/050657; priority date of January 13, 2022) for use as PPI inhibitor of beta-TrCP/NRF2 and use un therapy of liver disease.